Tadalafil in the Management of Benign Prostatic Hyperplasia–Associated LUTS: Evidence from Clinical Trials

Introduction The clinical management of benign prostatic hyperplasia (BPH)–associated lower urinary tract symptoms (LUTS) has traditionally revolved around α-adrenergic antagonists and 5α-reductase inhibitors. While these treatments remain cornerstones, they are burdened by well-known sexual side effects, often limiting adherence. The…

A Modern Approach to Vascular Erectile Dysfunction: Integrating Tadalafil, Traditional Chinese Medicine Lavage, and Vacuum Negative Pressure Therapy

Introduction Erectile dysfunction (ED) remains one of the most prevalent male sexual health conditions, with a significant proportion of cases rooted in vascular pathology. While phosphodiesterase type 5 inhibitors (PDE5i) such as tadalafil have transformed the therapeutic landscape, their efficacy…